Melasma and Post Inflammatory Hyperpigmentation: Management Update and Expert Opinion.

Area of Science:

• Dermatology and Cosmetic Science
• Pigmentary Disorders
• Skin Rejuvenation

Background:

• Dyschromia, including melasma and post-inflammatory hyperpigmentation (PIH), is a common cosmetic concern, particularly in diverse skin types.
• The rise in cosmetic procedures performed by non-specialists increases the incidence of these conditions.
• Treatment is complex, targeting melanocytic hyperactivity, pigment breakdown, and inflammation.

Purpose of the Study:

• To review current and emerging treatments for dyschromia, focusing on melasma and PIH.
• To provide an expert opinion on optimal management strategies for enhanced patient outcomes.
• To discuss the efficacy and safety profiles of various therapeutic agents and procedures.

Main Methods:

• Review of existing literature on topical lightening agents, including hydroquinone (HQ), azelaic acid (AzA), and retinoids.
• Analysis of combination therapies involving topical treatments and in-office procedures like chemical peels, lasers (IPL, fractional, pigment), and microneedling.
• Evaluation of newer cosmeceutical agents with claimed lower irritant potential.

Main Results:

• Topical therapy combined with sun protection is crucial for managing dyschromia.
• US FDA-approved treatments include hydroquinone (HQ) and Tri-Luma® for hyperpigmentation and melasma, respectively.
• Combination treatments involving procedures significantly enhance results compared to monotherapy.

Conclusions:

• Melasma can be effectively controlled and maintained with appropriate treatment.
• Post-inflammatory hyperpigmentation (PIH) is often curable with proper management.
• A comprehensive, individualized treatment plan is essential for optimal results in managing dyschromia.